SCHEMBL11025349

SCHEMBL11025349

CN1CCN(c2ccc(Nc3cc(Cc4ccc(Cl)cc4)cnc3C(N)=O)cc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC2A1 P11166 2/20 0.52
▸ MAPKAPK2 P49137 2/20 0.50
▸ RAD52 P43351 1/20 0.48
▸ GFER P55789 1/20 0.48
▸ EGFR P00533 1/20 0.46
▸ CDK4 P11802 2/20 0.45
▸ CDK6 Q00534 2/20 0.45
▸ CSF1R P07333 2/20 0.45
▸ STAT6 P42226 1/20 0.45
▸ CCNT1 O60563 1/20 0.45
▸ CCND1 P24385 1/20 0.45
▸ CDK9 P50750 1/20 0.45
▸ AURKA O14965 1/20 0.45
▸ CCNA2 P20248 1/20 0.45
▸ CDK2 P24941 1/20 0.45
▸ CCND3 P30281 1/20 0.45
▸ AOC3 Q16853 2/20 0.45
▸ SYK P43405 1/20 0.44
▸ JAK3 P52333 1/20 0.44
▸ MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11029543 0.91 MAPKAPK2 (0.49) SLC2A1MAPKAPK2EGFRCDK4CDK6
SCHEMBL11028773 0.90 MAPKAPK2 (0.50) SLC2A1MAPKAPK2EGFRCDK4CDK6
SCHEMBL11025081 0.90 STAT6 (0.55) SLC2A1MAPKAPK2EGFRCDK4CDK6
SCHEMBL11029481 0.90 SLC2A1 (0.52) SLC2A1MAPKAPK2RAD52GFEREGFR
SCHEMBL11028483 0.89 EGFR (0.49) SLC2A1MAPKAPK2RAD52EGFRCDK4
SCHEMBL11027886 0.89 SLC2A1 (0.47) SLC2A1MAPKAPK2EGFRCDK4CDK6
SCHEMBL11030740 0.87 SLC2A1 (0.55) SLC2A1MAPKAPK2EGFRCDK4CDK6
SCHEMBL11027435 0.86 STAT6 (0.49) SLC2A1MAPKAPK2EGFRCDK4CDK6
SCHEMBL11033990 0.86 SLC2A1 (0.54) SLC2A1EGFRCDK4CDK6CSF1R
SCHEMBL11029564 0.86 TNIK (0.52) SLC2A1EGFRCDK4CDK6CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US claimed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP claimed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN claimed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US claimed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO claimed
US-8859546-B2 Picolinamide inhibitors of kinases ABBVIE INC. (US) 2014-10-14 — — US disclosed
EP-2665711-A1 PICOLINAMIDE INHIBITORS OF KINASES Abbvie Inc. (US) 2013-11-27 — — EP disclosed
CN-103380117-A Picolinamide inhibitors of kinases ABBOTT LAB 2013-10-30 — — CN disclosed
WO-2012100135-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — WO disclosed
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190681-A1 PICOLINAMIDE INHIBITORS OF KINASES ALK, PKN2, ERBB2 SLC2A1 3662/4885MAPKAPK2 115/4885RAD52 4739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback